Sibylle Loibl, MD, PhD, of the German Breast Group, discusses a study evaluating palbociclib plus endocrine treatment vs a chemotherapy-based treatment strategy in patients with hormone receptor–positive, HER2-negative metastatic breast cancer (Abstract OT3-05-04).
Sherene Loi, MD, PhD, and Roberto Salgado, MD, PhD, both of the Peter MacCallum Cancer Centre, discuss study findings on pembrolizumab and trastuzumab in patients with trastuzumab-resistant disease (Abstract GS2-06).
Silvia C. Formenti, MD, of Weill Cornell Medicine, discusses the high therapeutic potential of combining radiotherapy with immunotherapy and findings that show radiation dose and fractionation seem particularly relevant to the success of abscopal responses. The science has now matured to clinical translation.
Eric S. Winer, MD, of the Dana-Farber Cancer Institute, addresses the much-discussed controversy over whether all women diagnosed with metastatic breast cancer should undergo next-generation sequencing.
Eun-Sil Shelley Hwang, MD, of Duke University Medical Center, discusses study findings on primary endocrine therapy for estrogen receptor–positive ductal carcinoma in situ (Abstract GS5-05).
Richard Pazdur, MD, of the U.S. Food & Drug Administration’s Oncology Center of Excellence, discusses the rapid changes in evaluating and approving new and effective agents, incorporating the view of patients in the process, and modernizing clinical trial design with broader eligibility criteria.
